Compare Avalanche Treasury Corporation Class A Common Stock (AVAT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avalanche Treasury Corporation Class A Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? Avalanche Treasury Corporation Class A Common Stock trades at $0.34 (market cap $15.33M), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 118.1× Avalanche Treasury Corporation Class A Common Stock's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| AVAT | RXRX | |
|---|---|---|
Market Cap | $15.33M | $1.81B |
Sector | Financials | Health |
52-Week High | $10.75 | $6.79 |
52-Week Low | $0.30 | $2.84 |
Enterprise Value | $15.33M | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVAT trades at $0.342, up 1.57% on the day, with a bearish technical signal from moving averages. The company reported a net income of $8.28 million for the current period but negative operating cash flow of -$930,710, indicating potential cash burn. Recent news highlights its Nasdaq listing as Avalanche Treasury Co., focusing on capital allocation within its ecosystem.
The outlook is mixed; a low P/B of 0.4 suggests potential undervaluation, but negative cash flow and a bearish technical trend pose risks. Investment opportunity hinges on the company's ability to improve operational efficiency post-listing, while risks include sustained cash burn and competitive pressures in treasury management.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
